Current Headlines

  1. New Blockchain And AI-Based Platform To Revolutionize Drug Discovery

    Innoplexus AG announced today a groundbreaking update coming soon to their iPlexus platform that will leverage the power of blockchain technology and artificial intelligence to resolve inefficiencies in early-stage drug discovery

  2. A Capsule Against Cancer: NUST MISIS Scientists' Development Doubles Lifetime Of Sick Animals

    A research team from NUST MISIS and Pirogov Russian National Research Medical University (RNRMU) has successfully conducted preclinical trials of a new anticancer drug based on magnetite nanoparticles

  3. CENTOGENE Announces Drug Development Collaboration With Orphazyme In Neuronopathic Gaucher Disease

    CENTOGENE, the worldwide leader in elucidating rare disease genetics for patients, clinicians and pharmaceutical partners, recently announced a clinical development collaboration with Orphazyme A/S to improve the lives of patients and families living with neuronopathic Gaucher disease, a rare, inherited, progressive and debilitating lysosomal storage disorder

  4. Seven New York City-Area Scientists Win Pershing Square Sohn Prize For Young Investigators In Cancer Research

    The Pershing Square Sohn Cancer Research Alliance today announced the seven winners of the 2018 Pershing Square Sohn Prize for Young Investigators in Cancer Research, awarded annually to promising early career, New York City-area cancer research scientists. Recipients receive $200,000 in funding per year for up to three years, for a total of $600,000, to support bold research at a stage when traditional funding is often lacking. The awards will be presented on May

  5. Arch Biopartners Engages Nucro-Technics To Complete Toxicology Studies To Support Investigational New Drug Application For Metablok

    Arch Biopartners, Inc., (Arch or the Company) (TSX Venture:ARCH) (OTCQB:ACHFF) a portfolio-based biotechnology company, today announced it has engaged Nucro-Technics in Scarborough, Ontario to complete the preclinical toxicology and pharmacology studies to support an Investigational New Drug (IND) application for Metablok, the Company’s drug candidate for preventing acute kidney injury

  6. CytomX Therapeutics Announces FDA Clearance Of Investigational New Drug Application For CX-2029, A CD71-Directed Probody Therapeutic

    CytomX Therapeutics, Inc. (Nasdaq:CTMX) a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody™ therapeutic technology platform, today announced that the U.S. Food and Drug Administration has cleared its Investigational New Drug (IND) application for CX-2029, a first-in-class CD71-directed Probody™ drug conjugate being co-developed by CytomX and its partner AbbVie

  7. Cidara Therapeutics And Rutgers University Awarded $5.5M Grant From NIH To Support Development Of Novel Immunotherapy Agents Targeting Multi-Drug Resistant Gram-Negative Bacterial Infections

    Cidara Therapeutics, Inc., a biotechnology company developing novel anti-infectives including immunotherapies, recently announced that it and Rutgers University have been awarded a five-year, $5.5M partnership grant from the U.S. National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH), an agency of the United States Department of Health and Human Services

  8. Network Launched To Help Development Of New Drugs For Children In Europe

    A new network, involving paediatric specialists from across the world, has been launched to help facilitate the development of new drugs for children in Europe

  9. Altogen Labs Xenograft Services For Drug Development Studies Of Anti-Cancer Therapeutics

    Altogen Labs announced addition of five new in-house validated xenograft models (4T1, BxPC-3, Calu-6, MDA-MB-468, and PANC-1). This will make a total of 89 CDX xenograft models and 29 PDX xenograft models provided by Altogen Labs

  10. Glenmark Pharmaceuticals Announces The Company's First New Drug Application For Ryaltris™ For Patients With Seasonal Allergic Rhinitis

    Glenmark Pharmaceuticals, a global pharmaceutical company, today announced that the company has submitted a New Drug Application (NDA) to the U.S. Food & Drug Administration (FDA) for its leading respiratory pipeline candidate Ryaltris™ (rye - al' - tris), an investigational fixed-dose combination nasal spray of an antihistamine and a steroid, as a treatment for seasonal allergic rhinitis (SAR) in patients 12 years of age and older